Anti-amyloid Treatment

Anti-amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)


This 36-month study is testing an investigational drug in older people who have evidence of elevated amyloid build-up in their brains, but who do not yet show symptoms of Alzheimer’s disease. It will investigate whether the drug solanezumab slows the progression of memory loss associated with brain amyloid built-up, thereby delaying Alzheimer’s disease-related damage in the brain or progression of memory loss.


  • Men and women
  • Ages 65 – 85
  • Stable medications for six weeks prior to baseline visit
  • Reliable study partner with at least weekly contact willing to attend visits and provide information about the participant
  • Willing and able to participate in all study procedures for the duration of the study
  • PET scan that shows evidence of brain amyloid pathology at second visit
  • Meets scoring criteria on memory assessments at screening


  • 48 study visits over 36 months
  • Tests of memory and thinking skills
  • Height, weight and vital signs
  • Physical and neurological exam
  • Electrocardiogram (ECG)
  • Collection of general medical history
  • Review of medications
  • Blood and urine samples
  • Lumbar puncture (optional)
  • MRI and PET scans
  • Study drug administration through infusion

Participant Benefits

  • Memory and medical screenings at no cost to you
  • Compensation for time and travel

Contact Information

Tim Collare: 336-716-6463 or email




Last Updated: 07-13-2016
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.